70.98

1.47% -1.06

Halozyme Therapeutics Inc (HALO)

Overview News Price History Option Chain Financials Why HALO Down? Discussions Forecast

Halozyme Therapeutics Inc stock is traded at $70.98, with a volume of 2.23M. It is down -1.47% in the last 24 hours and up +0.78% over the past month. Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.

Previous Close:

$72.04

Open:

$71.71

24h Volume:

2.23M

Relative Volume:

1.05

Market Cap:

$8.35B

Revenue:

$947.36M

Net Income/Loss:

$392.47M

P/E Ratio:

23.50

EPS:

3.02

Net Cash Flow:

$392.71M

1W Performance:

-10.65%

1M Performance:

+0.78%

6M Performance:

-0.21%

1Y Performance:

+23.57%

1-Day Range:

$70.56

$72.72

1-Week Range:

$70.56

$81.51

52-Week Range:

$47.50

$82.22

Halozyme Therapeutics Inc Stock (HALO) Company Profile

Name

Halozyme Therapeutics Inc

Sector

Healthcare (1108)

Industry

Biotechnology (619)

Phone

(858) 794-8889

Address

12390 EL CAMINO REAL, SAN DIEGO, CA

Employee

350

Twitter

@halozymeinc

Next Earnings Date

2025-02-18

Latest SEC Filings

HALO's Discussions on Twitter

Compare HALO vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
HALO Halozyme Therapeutics Inc	70.98	8.47B	947.36M	392.47M	392.71M	3.02
VRTX Vertex Pharmaceuticals Inc	476.90	119.21B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	779.67	82.71B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	844.41	52.43B	3.06B	1.28B	447.35M	19.67
ALNY Alnylam Pharmaceuticals Inc	336.19	45.01B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	362.14	39.23B	4.98B	69.60M	525.67M	0.5198

Halozyme Therapeutics Inc Stock (HALO) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-04-25	Downgrade	Goldman	Neutral → Sell
Oct-14-25	Upgrade	Leerink Partners	Underperform → Market Perform
Aug-06-25	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Jul-10-25	Resumed	Goldman	Neutral
May-14-25	Downgrade	Morgan Stanley	Overweight → Equal-Weight
May-13-25	Downgrade	Leerink Partners	Market Perform → Underperform
Oct-07-24	Downgrade	Wells Fargo	Overweight → Equal Weight
Sep-19-24	Downgrade	JP Morgan	Overweight → Neutral
Jun-07-24	Downgrade	Piper Sandler	Overweight → Neutral
Feb-29-24	Initiated	TD Cowen	Outperform
Jul-24-23	Downgrade	Goldman	Buy → Neutral
Jul-24-23	Initiated	H.C. Wainwright	Buy
May-10-23	Upgrade	Piper Sandler	Neutral → Overweight
Mar-27-23	Resumed	Berenberg	Buy
Mar-16-23	Downgrade	SVB Securities	Outperform → Market Perform
Dec-21-22	Resumed	Morgan Stanley	Overweight
Nov-28-22	Initiated	Wells Fargo	Overweight
Sep-09-22	Initiated	Morgan Stanley	Overweight
May-23-22	Initiated	SVB Leerink	Outperform
Jun-14-21	Initiated	Evercore ISI	Outperform
May-17-21	Initiated	SVB Leerink	Outperform
May-11-21	Downgrade	Piper Sandler	Overweight → Neutral
Jan-21-21	Reiterated	The Benchmark Company	Buy
Dec-17-20	Initiated	Berenberg	Buy
Sep-14-20	Resumed	JP Morgan	Overweight
Jul-01-20	Initiated	The Benchmark Company	Buy
Feb-05-20	Upgrade	Piper Sandler	Neutral → Overweight
Jan-09-20	Upgrade	BMO Capital Markets	Market Perform → Outperform
Jan-08-20	Initiated	Goldman	Buy
Nov-05-19	Upgrade	Barclays	Underweight → Equal Weight
Oct-19-18	Resumed	Piper Jaffray	Neutral
May-11-18	Downgrade	Barclays	Equal Weight → Underweight
Jan-24-18	Initiated	Goldman	Neutral
Oct-16-17	Reiterated	Piper Jaffray	Overweight
Jan-06-17	Downgrade	Citigroup	Buy → Neutral
Nov-03-16	Initiated	Deutsche Bank	Buy
Dec-04-15	Initiated	Wells Fargo	Outperform
Nov-18-15	Initiated	Citigroup	Buy
Sep-22-15	Initiated	Barclays	Overweight
Jun-22-15	Reiterated	JP Morgan	Overweight
Mar-03-15	Reiterated	UBS	Buy
Feb-18-15	Reiterated	MLV & Co	Buy
Jan-08-15	Reiterated	MLV & Co	Buy

View All

Halozyme Therapeutics Inc Stock (HALO) Latest News

03:48 AM

Halozyme outlines $1.71B–$1.81B 2026 revenue target as new subcutaneous technologies expand pipeline - MSN

03:48 AM

Feb 21, 2026

Stock Report: Is Halozyme Therapeutics Inc forming a breakout patternEarnings Miss & AI Powered Buy and Sell Recommendations - baoquankhu1.vn

Feb 21, 2026

Halozyme Therapeutics (NASDAQ:HALO) Downgraded to Hold Rating by Wall Street Zen - MarketBeat

Feb 21, 2026

Feb 20, 2026

Jupiter Asset Management Ltd. Purchases 129,971 Shares of Halozyme Therapeutics, Inc. $HALO - MarketBeat

Feb 20, 2026

Benchmark raises Halozyme stock price target to $90 on strong results - Investing.com Nigeria

Feb 19, 2026

Benchmark raises Halozyme stock price target to $90 on strong results By Investing.com - Investing.com South Africa

Feb 19, 2026

Halozyme (HALO) loses 9% on weak earnings - MSN

Feb 19, 2026

Halozyme Therapeutics (NASDAQ:HALO) Price Target Raised to $75.00 at Wells Fargo & Company - MarketBeat

Feb 19, 2026

Wells Fargo Raises Price Target on Halozyme Therapeutics (HALO) to $75 | HALO Stock News - GuruFocus

Feb 19, 2026

Halozyme (HALO) Loses 9% on Weak Earnings - Finviz

Feb 19, 2026

Halozyme Therapeutics (NASDAQ:HALO) Trading Down 8.7% on Disappointing Earnings - Defense World

Feb 19, 2026

TD Cowen raises Halozyme stock price target on royalty growth By Investing.com - Investing.com Nigeria

Feb 19, 2026

Feb 18, 2026

Why Halozyme Therapeutics (HALO) Is Down 7.9% After Acquisition-Driven Q4 Loss And 2026 Outlook Reaffirmation - Yahoo Finance

Feb 18, 2026

Halozyme Earnings Call Highlights Royalty-Fueled Growth - TipRanks

Feb 18, 2026

Halozyme Therapeutics (HALO) Reports Q4 Earnings Miss - GuruFocus

Feb 18, 2026

Halozyme shares slide as surprise Q4 loss and acquisition-related charges overshadow revenue beat - Quiver Quantitative

Feb 18, 2026

Halozyme Therapeutics (NASDAQ:HALO) Stock Price Down 8.7% Following Weak Earnings - MarketBeat

Feb 18, 2026

Halozyme's Q4 Earnings Miss, Higher Royalties Drive Y/Y Revenues - Nasdaq

Feb 18, 2026

Is Halozyme Therapeutics (HALO) Stock Price Out Of Step With Recent Valuation Signals - Yahoo Finance

Feb 18, 2026

TD Cowen raises Halozyme stock price target on royalty growth - Investing.com South Africa

Feb 18, 2026

Halozyme Delivers Record FY2025 As 2026 Sets Up A Major Profitability Surge (NASDAQ:HALO) - Seeking Alpha

Feb 18, 2026

Halozyme Therapeutics, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance

Feb 18, 2026

Halozyme Therapeutics, Inc. (NASDAQ:HALO) Q4 2025 Earnings Call Transcript - Insider Monkey

Feb 18, 2026